Nuwellis (NUWE) & The Competition Financial Comparison

Nuwellis (NASDAQ:NUWE) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Nuwellis to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Valuation & Earnings

This table compares Nuwellis and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nuwellis	$8.27 million	-$17.52 million	-0.00
Nuwellis Competitors	$1.87 billion	$138.21 million	9.47

Nuwellis’ peers have higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Nuwellis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Nuwellis Competitors	-278.24%	-150.08%	-21.87%

Analyst Ratings

This is a summary of current ratings and price targets for Nuwellis and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1	0	0	0	1.00
Nuwellis Competitors	4270	10539	18313	828	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.08%. Given Nuwellis’ peers stronger consensus rating and higher possible upside, analysts plainly believe Nuwellis has less favorable growth aspects than its peers.

Insider & Institutional Ownership

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Nuwellis has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Nuwellis’ peers have a beta of 2.56, meaning that their average share price is 156% more volatile than the S&P 500.

Summary

Nuwellis peers beat Nuwellis on 12 of the 13 factors compared.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.